Roth Capital Expects Reduced Earnings for Journey Medical

Key Points

• Roth Capital has lowered its earnings estimate for Journey Medical's Q4 2025 to $0.02 per share, down from $0.03, while the full-year consensus estimate is ($1.02) per share.
• Journey Medical reported Q2 earnings of ($0.16) per share, missing estimates by ($0.09), despite revenues of $15.01 million exceeding expectations.
• Recent analyst ratings include a maintained "buy" from Lake Street Capital with a price target of $13.00, while Wall Street Zen downgraded their rating from "buy" to "hold".

Journey Medical Corporation (NASDAQ:DERM - Free Report) - Analysts at Roth Capital cut their Q4 2025 EPS estimates for shares of Journey Medical in a research report issued on Tuesday, August 12th. Roth Capital analyst J. Wittes now expects that the company will post earnings of $0.02 per share for the quarter, down from their prior forecast of $0.03. The consensus estimate for Journey Medical's current full-year earnings is ($1.02) per share. Roth Capital also issued estimates for Journey Medical's FY2026 earnings at $2.00 EPS, FY2027 earnings at $3.00 EPS, FY2028 earnings at $4.66 EPS and FY2029 earnings at $5.24 EPS.

Journey Medical (NASDAQ:DERM - Get Free Report) last posted its quarterly earnings results on Tuesday, August 12th. The company reported ($0.16) earnings per share for the quarter, missing analysts' consensus estimates of ($0.07) by ($0.09). Journey Medical had a negative return on equity of 48.69% and a negative net margin of 15.49%. The company had revenue of $15.01 million for the quarter, compared to analyst estimates of $14.93 million.

Other equities analysts have also recently issued reports about the stock. Alliance Global Partners reaffirmed a "buy" rating on shares of Journey Medical in a research note on Thursday, May 15th. Lake Street Capital reiterated a "buy" rating and issued a $13.00 price objective (up from $9.00) on shares of Journey Medical in a research report on Wednesday. Finally, Wall Street Zen lowered shares of Journey Medical from a "buy" rating to a "hold" rating in a research report on Sunday, July 6th.

Journey Medical Price Performance

Shares of NASDAQ:DERM traded down $0.31 on Thursday, reaching $6.95. 267,426 shares of the company were exchanged, compared to its average volume of 175,392. The company has a current ratio of 1.27, a quick ratio of 1.03 and a debt-to-equity ratio of 1.11. Journey Medical has a 1-year low of $3.54 and a 1-year high of $8.90. The firm has a market cap of $161.94 million, a price-to-earnings ratio of -18.29 and a beta of 0.80. The company has a 50-day moving average of $7.15 and a 200-day moving average of $6.54.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Wasatch Advisors LP increased its stake in shares of Journey Medical by 23.8% during the 2nd quarter. Wasatch Advisors LP now owns 1,152,059 shares of the company's stock valued at $8,272,000 after acquiring an additional 221,456 shares during the last quarter. Opaleye Management Inc. increased its stake in shares of Journey Medical by 37.0% during the 2nd quarter. Opaleye Management Inc. now owns 95,000 shares of the company's stock valued at $682,000 after acquiring an additional 25,677 shares during the last quarter. Bank of America Corp DE increased its stake in shares of Journey Medical by 4,707.0% during the 2nd quarter. Bank of America Corp DE now owns 4,134 shares of the company's stock valued at $30,000 after acquiring an additional 4,048 shares during the last quarter. Raymond James Financial Inc. acquired a new stake in Journey Medical during the 2nd quarter worth approximately $36,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new stake in Journey Medical in the second quarter valued at approximately $48,000. 7.25% of the stock is currently owned by hedge funds and other institutional investors.

Journey Medical Company Profile

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.